Streetbeat News

Stock Prices

LLY

Eli Lilly is planning new trials for its weight-loss drugs, Mounjaro and Zepbound, targeting non-obese patients. The company aims to explore the use of these drugs for health maintenance and prevention of conditions like diabetes. Eli Lilly is also discouraging the off-label use of Zepbound for cosmetic purposes.

Portfolio Pulse from Vandana Singh

October 01, 2024 | 1:36 pm

NA

Nano Labs shares rose after the CEO bought 1,107,935 Class A shares with personal funds.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:35 pm

ARCO

Arcos Dorados shares are experiencing an uptick following the company's announcement to renew its master franchise agreement with McDonald's.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:30 pm

CSGP

CoStar Group (NYSE:CSGP) has seen an 8.72% increase in its short percent of float, now at 2.37% of available shares. This indicates a rise in bearish sentiment, although it remains below the peer group average of 6.41%.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 1:30 pm

NVAX

Novavax's short interest has increased by 6.09%, with 33.53 million shares sold short, representing 26.13% of its float. This is higher than its peers' average of 13.61%. The high short interest could indicate bearish sentiment but also presents potential for a short squeeze.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 1:30 pm

ZM

Zoom Video Communications (NYSE:ZM) has seen a 12.19% decrease in its short percent of float, now at 3.53%. This suggests a shift in market sentiment, as fewer shares are being shorted. Despite having higher short interest than its peers, this decline could indicate a more bullish outlook.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 1:30 pm

ZK

Zeekr shares are experiencing an upward trend following the announcement of a significant increase in vehicle deliveries for September 2024, marking a 77% year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:29 pm

GRTS

Gritstone Bio shares declined following a downgrade by JMP Securities from Market Outperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:28 pm

SGMT

Sagimet Biosciences shares rose following the FDA's Breakthrough Therapy Designation for Denifanstat, targeting noncirrhotic metabolic dysfunction associated steatohepatitis with liver fibrosis.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:28 pm

GHSI

Guardion Health Sciences shares fell after announcing a plan of dissolution and liquidation, delisting from Nasdaq, and appointing an interim president and CEO.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:24 pm